Phase III study of first-line zolbetuximab plus CAPOX versus placebo plus CAPOX in Claudin 18.2(+)/HER2(-) advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW Meeting Abstract
| Authors: | Shah, M. A.; Ajani, J. A.; Al-Batran, S. E.; Bang, Y. J.; Catenacci, D.; Enzinger, P. C.; Ilson, D. H.; Kim, S.; Lordick, F.; Shitara, K.; Van Cutsem, E.; Arozullah, A.; Park, J. W.; Xu, R. H. |
| Abstract Title: | Phase III study of first-line zolbetuximab plus CAPOX versus placebo plus CAPOX in Claudin 18.2(+)/HER2(-) advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Language: | English |
| ACCESSION: | WOS:000560368309120 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.TPS4648 |
| Notes: | Meeting Abstract: TPS4648 -- Source: Wos |
